Yantai Dongcheng Biochemicals (002675.SZ): A new dual-target radiopharmaceutical for in vivo diagnosis has received clinical trial approval.

Yantai Dongcheng Biochemicals (002675.SZ) announced that its controlling subsidiary Yantai Lanna Cheng Biotechnology Co., Ltd. (referred to as "LNC") has received the drug clinical trial approval notification for 18F-LNC1007 injection from the China National Medical Products Administration and will conduct clinical trials in the near future. The company's research product, 18F-LNC1007 injection, is a novel dual-targeted radioactive diagnostic drug that targets fibroblast activation protein (FAP) and integrin v3 at the same time. It is intended for the diagnosis of adult solid tumors that are positive for FAP and v3.